Loss of exclusivity and generic competition for Auryxia
Once exclusivity ended, an authorized generic entered the U.S. market, which can pressure price, volume, and contract retention.
- Scope
- Auryxia U.S. revenue
- Materiality
- high
Akebia Therapeutics, Inc.
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications. Its current business is built around treating complications of chronic kidney disease, especially anemia in dialysis patients, while using product revenue and collaboration income to fund development. The company markets and distributes its products through third parties rather than owning manufacturing or distribution assets. Akebia’s commercial story is closely tied to Vafseo, its approved HIF-PH inhibitor, and Auryxia, its established kidney-disease therapy that recently lost U.S. exclusivity and now faces generic competition.
10,5 %
83,3 %
−2,3 %
+47,5 %
1.55
1.46
| % | |
|---|---|
| Commercial kidney disease therapies | 95% Approved products sold to treat complications of chronic kidney disease, including anemia and related metabolic issues. |
| Collaboration and license revenue | 5% Royalty, license fee, and supply revenue generated under partner agreements in Japan and other markets. |
| Pipeline development programs | 0% Mid-stage and early-stage programs targeting rare kidney diseases and adjacent indications. |
Akebia sells primarily into the kidney-care ecosystem rather than directly to consumers...
- Dialysis providers and dialysis organizationsprimary
They purchase or influence use of therapies for patients receiving dialysis, especially Vafseo and Auryxia, because these patients have high unmet need and chronic treatment requirements.
- Nephrologists and other prescribersprimary
They decide whether to initiate treatment based on clinical profile, safety, labeling, and comparative convenience versus ESA or phosphate-binder alternatives.
- Specialty pharmacies and wholesalerssecondary
They handle distribution of commercial product supply and are essential to product availability and reimbursement flow.
- International commercial partnerssecondary
Partners such as Medice, MTPC, JT, and Torii generate collaboration, royalty, and supply revenue through licensed commercialization arrangements.
- Clinical trial and research collaboratorsemerging
Academic, clinical, and commercial collaborators support development of the pipeline and future label-expansion opportunities.
Akebia is headquartered in the United States and its commercial base is centered on the U.S. kidney-disease market...
- •United States is the core commercial market for Vafseo and Auryxia
- •Non-U.S. revenue is supported by collaboration and supply partners
- •Commercial execution depends on country-specific marketing approvals
- •Manufacturing is outsourced to third-party CMOs rather than owned plants
- •Distribution is handled through wholesalers, specialty pharmacies, and logistics partners
Akebia’s strategy is to expand its kidney-disease franchise by growing Vafseo, defending and monetizing Auryxia after...
01
Expand Vafseo commercializationshort-term
Vafseo is the company’s key growth product and the main driver of future kidney-franchise expansion.
02
Monetize Auryxia after loss of exclusivityshort-term
Auryxia remains a revenue source, but generic competition makes retention and contract execution critical.
03
Advance the kidney pipelinemedium-term
Pipeline success is needed to diversify beyond current commercial products and support long-term growth.
04
Preserve financial flexibilityshort-term
The company continues to rely on external capital and must balance R&D investment with debt and liquidity needs.
Akebia faces the classic risks of a small commercial-stage biopharma company: dependence on a limited number of...
Commercial adoption risk for Vafseo
Revenue depends on physician prescribing, patient acceptance, and payer coverage in a competitive anemia market.
- Scope
- Vafseo sales
- Materiality
- high
Regulatory and label-expansion risk
The company must maintain approvals and may need additional approvals for broader use or new indications.
- Scope
- Pipeline and international commercialization
- Materiality
- high
Capital and dilution risk
The company has a history of losses and may need additional financing to fund operations and development.
- Scope
- Liquidity and shareholder dilution
- Materiality
- high
Third-party manufacturing and distribution dependence
Akebia does not own manufacturing facilities and relies on CMOs and logistics partners for supply continuity.
- Scope
- Commercial supply chain
- Materiality
- medium
Product revenue reserves and rebates
Can materially change reported product revenue and gross margin
Collaboration and license revenue recognition
Creates quarter-to-quarter variability in other revenue
Inventory reserves and excess stock write-offs
Affects cost of goods sold and operating margin
Intangible asset amortization
Reduces operating income and distorts comparability
Fair value of warrant liability
Can create non-cash earnings volatility
ACADIA PHARMACEUTICALS INC
ACAD · Pharmaceutical Preparations
AGIOS PHARMACEUTICALS, INC.
AGIO · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
APGE · Biological Products, (No Diagnostic Substances)
ARDELYX, INC.
ARDX · Pharmaceutical Preparations
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
vTv Therapeutics Inc.
VTVT · Pharmaceutical Preparations
: 11/08/2026